GlassScriptPhysician profile
Alan Rejonis
NPI 1366949075
$5,092.55
in general payments reported to CMS, 2019-2025
21 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what 77% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $542 · 2024: $2,683 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,277 · Travel and Lodging: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,277.08 |
| Travel and Lodging | $815.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,070.93 | 2023-2025 | General - Therapies, Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $1,330.82 | 2024-2025 | Intellis Adaptivestim, Vanta Adaptivestim |
| Collegium Pharmaceutical, INC. | $338.53 | 2024-2025 | Belbuca |
| Vertos Medical, INC. | $297.45 | 2023-2024 | Mild Device Kit |
| Abbvie INC. | $162.04 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.48 | 2024-2025 | Relistor |
| Abbott Laboratories | $139.31 | 2024-2025 | Eterna |
| Pfizer INC. | $105.69 | 2024-2025 | |
| Nalu Medical, INC. | $94.13 | 2025 | Nalu Neurostimulation System |
| Ibsa Pharma INC. | $88.17 | 2023-2025 | Tirosint, Licart, Tirosint |
| Azurity Pharmaceuticals, INC. | $73.61 | 2023-2024 | Horizant, Horizant |
| Spr Therapeutics, INC | $55.73 | 2025 | Sprint Pns System |
| Scilex Pharmaceuticals INC. | $37.72 | 2024 | |
| Saluda Medical Americas, INC. | $23.25 | 2025 | Evoke |
| Fidia Pharma USA INC. | $21.51 | 2024 | Hyalgan, Hymovis, Triluron |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $19.96 | 2025 | Levorphanol Tartrate |
| Valinor Pharma, LLC | $18.60 | 2025 | Movantik |
| Alkermes, INC. | $17.54 | 2024 | Vivitrol |
| Forte Bio-Pharma LLC | $16.25 | 2025 | Prolate, Nalocet, Tanlor |
| Globus Medical, INC. | $16.20 | 2025 | Senza |
| Indivior INC. | $14.63 | 2023 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Rejonis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.